Zydus Lifesciences Limited · NSE:ZYDUSLIFE
Zydus Lifesciences — Cadila Healthcare — Investor Presentation (November 2013)
18 slides from Zydus Lifesciences's investor presentation, November 2013
Slide 1: Cadila Healthcare Limited Investor Presentation
Cadila Healthcare Limited Investor Presentation November 2013
Slide 2: Well integrated pharma player with global footprints
Well integrated pharma player with global footprints >60 years $ 1 bn + >7% of sales Operational Global Revenues Spent on R&D annually experience 20+ mfg. sites >20% CAGR 1st Indian Company In Sales and Net To discover & develop Producing >13 Profits an NCE in-house : bn pills annually (FY ‘08 – FY
Slide 3: History of achieving milestones consistently
History of achieving milestones consistently 25 fold growth in sales over last 16 years… …with significant external recognition Economic Times Emerging Company of the year 2010 Kaizen Institute - Operational Rs. 200 cr. Excellence in Tablet in 1995 Manufacturing in 2010 3
Slide 4: Key businesses for our journey Beyond the Billion
Key businesses for our journey Beyond the Billion Zydus Established home Future home New Technology Other Businesses markets markets businesses ▪ India formulations ▪ Brazil ▪ EU ▪ Biosimilars ▪ US oral solids ▪ Mexico ▪ Japan ▪ Transdermals ▪ Emerging markets ▪ Vaccines ▪ Wellness ▪ Injectables ▪ A
Slide 5: India formulations
India formulations Aspirations Market size* : Rs. 720 bn+ Market growth* : 7% Maintain strong leadership position in key areas – CVS, Zydus size** : Rs. 32 bn+ GI, respiratory, female healthcare Market Share* : 4.5% Zydus growth** : 16% Continue to be one of the significant contributors to reven
Slide 6: US Oral Solids
US Oral Solids Market size* : >$ 50 bn Aspirations Market growth* : 15-17% Zydus size** : ~ $ 276 mn Be amongst the top 10 generic cos. in US with Zydus growth** : 6% continued strong focus on customer needs One of the significant contributors to revenues and profits 34%+ CAGR in Sales (Last 5 y
Slide 7: Brazil
Brazil Market size* : >$ 16 bn Aspirations Market growth* : 12-14% Zydus size** : Rs. 2,384 mn To be among top 15 companies in 2015 Zydus growth** : -4% Strengths to be leveraged Presence in branded generics and generic generics segments with a continued focus on brand building initiatives Loc
Slide 8: Mexico
Mexico Market size* : ~ US$ 10 bn Aspirations Market growth* : 8-10% Build a profitable business in 2015 40+ product launches and 60 + fillings by 2015 Strengths to be leveraged Focused segments (Branded) – CNS, metabolic disorders and respiratory Building product pipeline from India – 25+ f
Slide 9: Other Global Markets
Other Global Markets Aspirations : To be amongst the leading players in these generics markets EU 9th largest in France, among top 20 in Spain Mkt. Size* : ~$ 6.5 bn Expansion through new products : launched 110+ molecules in France (France + Spain Gx) and 80+ molecules in Spain so far (incl. se
Slide 10: Other Businesses
Other Businesses Wellness Aspirations : To create niches in wellness space through innovation Leadership in sugar substitutes (94%+ market share), peel-off and scrub range for skin-care and margarine categories in India Zydus Size **: Rs. 4,100 mn Re-launched EverYuth brand with contemporary pac
Slide 11: Joint Ventures and Alliances
Joint Ventures and Alliances Aspirations : Value creation through win-win alliances and be a partner of choice Zydus Takeda JV Zydus Hospira JV State-of-the-art mfg. facility for APIs of State-of-the-art cytotoxic facility approved Nycomed by leading authorities like MHRA, USFDA, Commissioned
Slide 12: Biosimilars
Biosimilars Aspirations : Strengths to be leveraged Drive substantial business by 2015 Dedicated facility for product development and mfg. through… Marketing in India and emerging 170+ experienced scientists markets Strong pipeline: 17 biosimilars and 2 novel products Licensing / co-develo
Slide 13: New Technologies
New Technologies Aspirations : To be a leading market player in complex technologies State-of-the-art product development and manufacturing facility set-up in SEZ near Ahmedabad Transdermals 4 patches already filed with US FDA Several other patches under development Fully approved Vaccine Te
Slide 14: NCE research
NCE research Aspirations : Add more NCEs in pipeline to drive towards becoming a research based pharma co. by 2020 Key strengths NCE Pipeline State-of-the art Lead Pre- Drug clinical research facility Project Target Indication optimi- IND Phase I Phase II Phase III NDA Discovery Develop- saiton
Slide 15: World class infrastructure to support growth journey
World class infrastructure to support growth journey Formulations Mfg. Oral Solids (India) Oral Solids Other dosage forms Ahmedabad (USFDA ) (outside India) (India) Baddi (USFDA) US (Nesher Pharma – Transdermals – controlled substances) Ahmedabad SEZ Goa Brazil Topicals – Sikkim Ahme
Slide 16: Pillars of Organisational Health
Pillars of Organisational Health Key initiatives identified to improve overall organisation health in four key areas. Creating value and Promoting Strengthening Enhancing bottom-up developing talent collaboration across accountability by innovation across the across the businesses and proper perform
Slide 17: Key Financial Numbers – H1 FY 2013-14
Key Financial Numbers – H1 FY 2013-14 Consolidated (Rs. Mio.) Amount Gr.% Segment-wise Gross Sales Total Income from Operations 33,838 7.7% India Form., EBIDT 5,463 -7.1% 37% EBIDT % to Income from Ops. 16.1% JVs, 7% Profit before tax 4,250 1.5% APIs, 5% PBT % to Income from Ops. 12.6% Animal US, He
Slide 18: Thank You.
Thank You. Safe Harbour Statement This presentation may include certain “forward looking statements” , based on current expectations, within the meaning of applicable laws and regulations. Actual results may differ and the company does not guarantee realization of these statements. The Company also
Cadila Healthcare — Investor Presentation (November 2013) on 6ix